Reviewer’s report

Title: Fructus Ligustri Lucidi Modulates Estrogen Receptor Expression With No Uterotrophic Effect in Ovariectomized Rats

Version: 0 Date: 12 Mar 2017

Reviewer: Hongtao Bi

Reviewer's report:

Osteoporosis is one kind of the most common bone remodeling diseases characterized by reduction of bone mass and microstructural deterioration of bone tissue. Fructus Ligustri Lucidi (FLL) documented to be used to strengthen bone and treat osteoporosis for a long time in China. The present study aimed to investigate the effect of FLL on ERα and ERβ expressions in bone and uterus of OVX rats. The experimental design is straightforward, and data are clearly presented. The result could provide scientific data for modern utilization of FLL. However, to my knowledge, salidroside, hydroxytyrosol, and specnuezhenide are the major active components of FLL. Especially, salidroside has been proven to be very effective in treatment of osteoporosis. So, I suggested that authors should improve the discussion with the published phytochemical researches.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:
Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal